The mystique of hepatic tolerogenicity by Starzl, TE et al.
SEMINARS IN LIVER DISEASE-VOL. 20, NO, 4, 2000 
The Mystique of Hepatic Tolerogenicity 
THOMAS E. STARZL, M.D., Ph.D., NORIKO MURASE, M.D., 
ANTHONY DEMETRIS, M.D., MASSIMO TRUCCO, M.D., 
and JOHN FUNG, M.D., Ph.D. 
ABSTRACT: The evolution of clinical transplantation has hinged on 2 seminal turning points. The first was the 
demonstration in 1953 by Billingham, Brent, and Medawar that chimerism-associated tolerance could be induced 
deliberately in neonatal mice by infusing adult donor hematolymphopoietic cells. This discovery escalated in a 
straight line over the next 15 years to successful bone marrow transplantation in humans. The second turning point 
was the demonstration that organ allografts could self-induce tolerance under an umbrella of immunosuppression, 
or in some species without immunosuppression. Unfortunately, it was incorrectly concluded by most immunologists 
and surgeons that bone marrow and organ engraftment involved different immune mechanisms. In a derivative error, 
it became widely believed that the tolerogenicity of the liver differedfundamentally not only from that of bone mar-
row but also from that of other whole organs. 
These errors became dogma and were not corrected until low level donor leukocyte chimerism was found in hl,(-
mans and animals bearing long surviving liver, kidney, heart, and other kinds of allografts. With successful bone 
marrow transplantation, the trace population consisted of recipient rather than donor leukocytes. Thus, the conse-
quences of organ and bone marrow engraftment were mirror images. From these observations, it was proposed that 
the engraftment of all kinds of organs as well as bone marrow cells (BMC) involved host versus graft (HVG) and 
graft versus host (6VH) reactions with reciprocal induction of variable degrees of specific non-reactivity (toler-
ance). The maintenance of the tolerance was an active and ongoing process requiring the persistence of the trans-
plantedfragment of the donor immune system. The immune responsiveness and unresponsiveness to both organ and 
bone marrow allografts are thought to b,e governed by the migration and localization of leukocytes. The clarifying 
principles of transplantation immunology that have emergedfrom the chimerism studies are relevant to the adaptive 
immune response to microbial, tumor, allogeneic, and self antigens. These principles should be used to guide efforts 
to system,atically induce tolerance to human tissues and organs, and perhaps ultimately to xenografts. 
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Objectives 
Upon completion of this article, the reader should be able to understand I) the meaning and mechanisms of acquired tolerance; 2) the 
adaptive immune response to microorganisms vis a vis the response to organ and bone marrow allografts; and 3) the reasons for the liver's 
unusual tolerogenicity relative to that of other organs. 
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The emergence of transplantation has seen the de-
velopment of increasingly potent immunosuppressive 
agents, better methods of tissue and organ preservation, 
refinements in histocompatibility matching, anti numer-
ous innovations in surgical technique. 1.2 Although these 
advances helped to make organ transplantation a practi-
cal and valuable clinical service, the feasibility of such 
procedures ultimately depended upon a natural quality 
of all organs, namely their ability to induce variable de-
grees of donor specific nonreactivity (i.e., tolerance).3 
In humans, allogeneic tolerance is a normal im-
munologic option that generally requires a protective 
umbrella of immunosuppression. However, sponta-
neous tolerance to organs, most commonly the liver, has 
been recorded in pigs, rats, and mice. In addition to its 
greater tolerogenicity relative to other organs, the liver 
is more resistant to antibody mediated hyperacute rejec-
tion.4 Such observations, suggesting that the liver is an 
"immune privileged" organ led to a controversy of more 
than 25 years duration. The issue was whether tolero-
genicity is a unique property of the liver, or a quality 
possessed by all organs, varying only in degree. 
ORGAN TOLEROGENICITY: THE ORIGIN 
OF THE CONCEPT 
A Pathfinder Kidney Experience 
In retrospect, the inherent tolerogenicity of organs 
was evident from the beginning, although passionately 
denied. Between January 1959, and "JanuarY 1963, there 
were 6 examples of survival of greater than one year af-
ter kidney transplantation to human recipients precondi-
tioned with total body irradiation (TBI): one in 
Boston5.6 and 5 divided between two .Paris centers.7·8 
Under today's regulatory restrictions, these trials proba-
bly would have been blocked at an institutional review 
board (IRB) level. The longest survival with TBI pre-
conditioning in an animal model had been only for 
73 days, following kidney transplantation between bea-
gle dogs.9 Furthermore, the first successful clinical case 
in Boston, in which the donor was a fraternal twin, pro-
vided the only long survival in a dozen attempts at that 
institution. In France the 5 long survivals also were ex-
ceptions to the usual outcome of recipient death. 
In addition to these 6 cases, a non-irradiated human 
kidney recipient in Boston had been treated with aza-
thioprine from the time of transplantation on April 5, 
1962.10 Although this seventh long-surviving renal allo-
graft (from an unrelated donor) was failing by January, 
1963, it provided enough function to keep the patient 
dialysis-free for another 8 months. I 1 Unlike the TBI tri-
als, a track record had been established in animals. Sur-
vival longer than 100 days had been documented by 
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Calne l2 (with Murray13) in about 5% of mongrel canine 
kidney recipients treated with 6-mercaptopurine or its 
imidizole derivative, azathioprine. 
The limited efficacy of azathioprine, alone or in 
combination with other cytotoxic drugs, was found to 
be the same in humans lO as in the preceding dog studies. 
In contrast, 8 of the first 10 human kidney recipients 
treated with the combination of azathioprine and pred-
nisone at the University of Colorado had prolonged sur-
vival. These cases, compiled between October 1962, 
and March 1963,3 constituted the first successful series 
of human organ transplantation and included 2 patients 
who still bear the longest continuously functioning kid-
ney allografts in the world (> 37 years). 
Renal Tolerogenicity 
From a practical point of view, the significance of 
the Colorado series was the high rate of patient and graft 
survival. Its far more important conceptual implications 
were capsulized in the title of the report published in 
October 1963: "The reversal of rejection in human renal 
homografts with subsequent development of homo-
graft tolerance."3 Although the findings could not be ex-
plained, they provided the bedrock upon which the 
organ-defined specialties of clinical transplantation could 
be developed, using immunosuppressive drugs in combi-
nation that were ineffective when administered alone. 
The reversal of rejection in the human kidney recip-
ients was readily monitored by renal function tests after 
instituting large doses of prednisone (200 mg/day) to 
baseline immunosuppression with azathioprine. The 
evidence was equally clear that the renal allografts 
had self-induced partial tolerance under the cover of 
immunosuppression. After passing through rejection 
c~sesI most of the patients had a progressively dimin-
ishing need for immunosuppression, usually to doses 
lower than those which initially failed to prevent rejec-
tion. The tolerance was complete enough to allow many 
of the kidney recipients to be' releas~d to an unrestricted 
environment without the lethal immunologic invalidism 
that had been widely predicted. More than a third of a 
century later, remarkably similar observations leading 
to what was called "prope tolerance" were reported by 
CaIne et al. 14.15 in patients treated with a combination of 
modem day immunosuppressants. In fact, 2 of the 10 re-
cipients in the 1963 report have been free of immuno-
suppression for 34 and 6 years, respectively. 16 
Successful transplantation of the liver,17.18 and 
eventually all of the other extrarenal organs depended 
on the same phenomena as with kidney transplantation: 
the reversal of rejection and the evolution of specific 
non-reactivity. In 1966, adjunct antilymphocyte globu-
lin [ALG] was added to azathioprine and prednisone l9 
-
-
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TABLE 1. Empirical Therapeutic Dogma 
of Immunosuppression 
ingredients of STraTegy 
I. Baseline therapy 
2. Secondary adjustments of prednisone 
dose, or antilymphoid agents** 
3. Case to case trial (and potential error) 
of weaning. 
Baseline AgenTs 
I. Azathioprine* 
2. Cyclosporine 
3. Tacrolimus 
* Alone or with prophylactic prednisone. Equivalent results were ob-
tained with cyclophosphamide instead of azathioprine. 
**Initially used for prophylactic "induction." 
in the first "triple drug cocktail," and as more efficient 
baseline drugs (e.g., cyclosporine and tacrolimus) and 
adjunct agents (e.g., monoclonal antilymphoid antibod-
ies) became available they were readily substituted for 
the previous best immunosuppressants. However, the 
basic strategy was always the same (Table 1). 
Hepatic Tolerogenicity 
Until 1965, the only published clue that the liver 
might be unusually tolerogenic was the observation in 
untreated mongrel canine recipients that the intestine 
and pancreas had very little histopathologic evidence of 
rejection if they were components of multivisceral allo-
grafts that also included the liver.20 The finding was 
confirmed 30 years later in a rat version of the same 
multi visceral procedure.21 .22 However, the first unam-
biguous evidence of hepatic tolerogenicity was the 
demonstration in 1964 that mongrel dogs bearing ortho-
topic liver allografts under azathioprine therapy fre-
quently could have their immunosuppression stopped 
after 4 months with long subsequent survival;23 5 years 
later most of the drug free recipients remained wel1. 24 
The significance of this observation in canine liver 
recipients was extensively discussed23: "Although the 
early recovery after liver homotransplantation has many 
hazards ... the frequency and rapidity with which dogs 
could be withdrawn from immunosuppression without 
an ensuing fatal rejection is remarkable .... The consis-
tency of this state of host-graft nonreactivity and the ra-
pidity with which it seemed to develop exceeds that re-
ported after canine renal homotransplantation. The 
explanation for this is not apparent, but conceivably, the 
large antigenic mass could playa role or, alternatively, 
perhaps the liver with its enormous regenerative capac-
ity is simply capable of sustained function in the face of 
continuing but minimal chronic rejection. [However,] 
findings in the serial biopsies obtained after discontinu-
ance of therapy do not support the latter hypothesis ... " 
Soon thereafter in France25 and then else-
where,26-29 spontaneous liver engraftment in untreated 
outbred pigs was reported in 1/3 to 114 of hepatic re-
placement experiments. Many of these porcine recipi-
ents first passed through one or more self-resolving re-
jection crises.28.30:31 In the 19705, the phenomenon of 
tolerance induced by the liver was demonstrated in un-
treated rats (see later discussion). 
AN EPISTEMOLOGIC COLLAPSE 
The discovery that variable donor specific non-
reactivity could be induced by organ allografts under an 
umbrella of non-specific drug immunosuppression was 
the second principal turning point from which clinical 
transplantation evolved. 1.2 The first had been the demon-
stration by Billingham, Brent and Medawar in 1953 that 
transplantation tolerance could be induced in neonatal 
mice by infusing these immunologically immature (i.e., 
defenseless) recipients with allogeneic hematolympho-
poietic cells from a histocompatible or FI hybrid adult 
donor.32.33 If the recipients survived to adult life, ostensi-
bly with a "replaced" hematolymphopoietic (i.e., im-
mune) system, skin grafts from the same donor strain (but 
not from third party donors) were permanently accepted. 
The next step was to simulate in adult mice the im-
munologically defenseless state of the neonatal animals 
by TBl, followed by the infusion of donor bone marrow 
cells (BMC). When these experiments were success-
ful,34 the stage was set for clinical bone marrow trans-
plantation. However, this application was delayed for a 
decade until hlJman leukocyte antigen (HLA) matching 
became available.35-38 As in the experimental models, 
graft versus host disease (GVHD) was a lethal conse-
quence of the procedure in humans unless there was a 
good tissue match. Efforts to precondition canine kid-
ney recipients with TBl and donor bone marrow infu-
sion yielded only a single 73 day survivor.9 After this 
strategy failed in clinical trials, the use ofTBI alone was 
rewarded by the long survival of a handful of human 
kidney recipients (see earlier section, "A Pathfinder 
Kidney Experience"). Not unreasonably, it was con-
cluded that successful organ transplantation was based 
on fundamentally different principles than bone marrow 
transplantation. 
The two turning points had now diverged in oppo-
site directions, one leading to clinical bone marrow 
transplantation, and the other to organ transplantation. 
Moreover, a conceptual error had been introduced that 
distorted the orderly development of transplantation 
immunology, and of all other branches of immunology. 
The error was the conclusion "by consensus" that organ 
engraftment occurred by different mechanisms than the 
chimerism-dependent ones associated with neonatal 
tolerance and its clinical analogue of bone marrow 
transplantation. 
500 
The Liver-Specific Dogma 
The mistake subsequently was compounded by the 
argument that the mechanisms of hepatic tolerogenicity 
differed fundamentally, not only from those of bone 
marrow, but also from those leading to engraftment of 
other organs. This contention was based MllKK~e demon-
stration, first in spontaneously tolerant pigsllnd then in 
untreated rodent recipients of liver allografts4°-42 that 
the tolerization self-induced by the liver extended to 
donor skin transplanted at the same time or later, and to 
other donor organs. Except for the presumed absence of 
donor leukocyte chimerism in the recipients, however, 
the acquired donor-specific non-reactivity was indistin-
guishable from that in the chimerism-associated neona-
tal tolerance of Billingham, Brent and Medawar,32.33 and 
the experimental models of bone marrow transplanta-
tion34 that by this time had been brought to the clinic. 
The spontaneous tolerance in pig liver recipients 
was unpredictable. However, it could be reliably repro-
duced in about 15% of congenic rat strain combinations. 
Consequently, rat models came to dominate research 
efforts to explain the phenomenon of spontaneous liver 
tolerance.43-47 The more recent demonstration that Ii v-
ers self-induce such tolerance in more than 80% of 
mouse strain combinations48 has generated a second 
windfall of mechanistic investigations.49- 54 The mouse 
studies have been of particular interest because the prin-
ciples of mammalian immunology have been derived so 
much from studies of this species. 
In the ostensible absence of donor leukocyte 
chimerism, Davies, Kamada, and Rosen55 demonstrated 
specific deletion of cytotoxic antidonor lymphocytes 
from the thoracic duct, lymph nodes, and hepatic tissue 
of spontaneously tolerant rat liver recipients. The possi-
bility implicit in these findings that the liver is a fo-
cus of peripheral tolerance induction has resurfaced 
with the studies by Crispe56 of interactions within the 
liver between thymus-dependent circulating T cells and 
thymus-independent T cells with natural killer (NK) cell 
markers. 
In addition, it was postulated that soluble major his-
tocompatibility complex (MHC) Class I antigens se-
creted by the hepatocytes were responsible for the spon-
taneous hepatic tolerance.39,40.55.57-59 A subsequent but 
still liver-specific modification of this soluble antigen hy-
pothesis6o.61 accommodated the discovery in 1992 of 
donor leukocyte chimerism in human liver recipients (see 
later discussion). In the revision, Caine suggested that the 
soluble Class ~ antigen was a critical co-factor without 
which engraftment and persistence of donor leukocytes 
could not occur, while concluding that the persistence of 
late stage microchimerism was epiphenomenal.60 
Studies in mice48 including those with "knocked-
out" MHC class I genes62 have not supported the liver-
specific hypotheses. Importantly, it has been established 
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that spontaneous tolerance also can be induced in mice 
by heart48.63 and kidney allografts,M although in a much 
smaller number of donor-recipient strain combinations 
than with mouse liver allografts. 
The Colorado Hypothesis 
The exhaustion and deletion of an antigen specific 
clone had been postulated in the late 1950s to explain 
the acquisition in animals of tolerance to heterologous 
protein (with the aid of 6-mercaptopurine65 ), and to al-
logeneic splenocytes (without the need for immuno-
suppression66). The acceptance of clonal exhaustion-
deletion as a "real phenomenon" by early workers was 
evidenced by extensive reviews in 196767 and 196868 by 
some of the most distinguished pioneers in immunol-
ogy. Clonal exhaustion-deletion also was invoked at a 
very early time to explain the characteristic immuno-
logic confrontation (rejection) and resolution (graft ac-
ceptance) that occurred with kidney engraftment. 69 
Liver engraftment from the Colorado perspective 
was a form of donor specific tolerance that differed 
from kidney engraftment only quantitatively, exempli-
fied by the ability of long-surviving canine23.24 and hu-
man liver recipients7o-n to stop all immunosuppression 
more frequently than kidney recipients (Fig. 1). As with 
the kidney allografts, the seminal mechanism of hepatic 
tolerogenicity was postulated to be clonal exhaustion-
d~letion ("clone stripping"). However, the ideas de-
picted in Figure 2 were not taken seriously. In addition 
to showing clonal exhaustion-deletion as the primary 
explanation of allograft acceptance, other features pro-
posed in this first book on liver transplantation (pub-
lished in 196973 ) were ahead of their time. 
For example, alloantigen presentation leading to in-
duction of the expanded clone was depicted via host 
macrophages (Fig. 2) rather than by the dendritic cells 
(DC) that would not be described by Steinman and 
Cohn74 until 1973. The discovery of apoptosis also lay 
ahead. Nevertheless, the immune competent cells pro-
liferating in response to alloantigen were depicted in 
Figure 2 as selectively vulnerable, accounting for the 
emergence of donor-specific non-reactivity (tolerance) 
under treatment with immunologically non-specific 
immunosuppressants. 
Despite the logic of clonal exhaustion-deletion, this 
mechanism of acquired tolerance abruptly disappeared 
from the literature. To our knowledge, clonal exhaus-
tion-deletion was not mentioned a single time as an 
explanation for acquired tolerance in the voluminous 
immunology and transplantation literature spanning 
1970-1990. The dismissive treatment could be ex-
plained in part by the theoretical status of clonal 
exhaustion-deletion. However, a more important factor 
""'" 
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FIG. 1. Time on and off immunosuppression (as of October 1995) of 12 long surviving liver recipients, Patients 150 and 169 
stopped medication less than 2 years posttransplantation because of noncompliance. The others were weaned because of complica-
tions of chronic immunosuppression. These 12 patients represented 28% of the 42 patients in our total experience who had continu-
ously borne hepatic allografts for 15 to almost 26 years. Four years later, these patients remain drug free. Data from ref. 16. 
appears to have been a lack of understanding about the 
role of the organ's "passenger leukocytes." 
Passenger leukocytes are of bone marrow origin, 
and have been known for more than 3 decades to be the 
principal immunogenic component of allografts,75-79 
Consequently, one explanation of organ engraftment 
was that it involved thc' destruction of the immunogenic 
donor leukocytes by the recipient immune system, with 
selective sparing of the specialized parenchymal cells. 
The disappearance of most of the resident donor leuko-
cytes and their replacement by recipient cells of the 
same lineages had been reported in 1969 in' the first 
long-surviving human liver allografts. 31 •8o Because this 
was considered for the next 2 decades to be a unique 
feature of the liver allograft, the passenger leukocyte re-
placement became a candidate co-factor for hepatic 
tolerogenicity.45.58 However, when the same cell re-
placement was demonstrated in intestinal allografts in 
199122•81 (Fig. 3, lower graph), it was obvious that it 
probably was a generic phenomenon, that is, it occurred 
in all successfully transplanted organs. This was 
promptly confirmed. 
Exemplifying the power of ossified dogma, how-
ever, the possibility was not generally entertained, even 
at this late time, that the missing donor leukocytes had 
simply migrated and survived in the recipient. Conse-
quently, organ engraftment continued to be explained 
by hypotheses in which donor leukocyte chimerism 
played no role. The hypotheses included the presence or 
development of suppressor, veto, and other immune 
regulatory cells; cytokine profile changes; a role for 
various idiotypic and/or enhancing antibodies; and fail-
ure of delivery of a second (co-stimulatory) signal fol-
lowing primary antigen presentation. 
AN EPIPHANY 
The requirement for nonchimerism mechanisms 
was eliminated when a link was established in 1992 be-
tween organ transplantation and classical neonatal 
and/or bone marrow transplant-induced tolerance. Us-
ing sensitive immunocytochemical and polymerase 
chain reaction (peR) techniques, low level (micro) 
chimerism was detected in the tissues or blood of all 
30 human organ recipients studied 2.5 to 30 years after 
transplantation of continuously functioning liver (n = 
25) or kidney allografts (n :::;: 5).70.X2-85 
From this finding, it was deduced that organ en-
graftment was a dynamic process that had begun at the 
time of transplantation with ''' ... widespread responses 
of coexisting donor and recipient immune responses, 
each to the other, causing reciprocal clonal expansion 
followed by peripheral clonal deletion,"7o.82 Although 
I 
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FIG. 2. Original caption published in 1969: "Hypothetical mechanisms by which nonspecific immunosuppression may lead 
to selective abrogation of the host immune response: Special susceptibility to these agents of a fraction of the lymphoid 
population could lead to exhaustion of a clone and, hence, tolerance. Since maintenance of such cell lines, even in adult 
life, is apparently thymic dependent In experimental animals, thymectomy would be expected to aid the process; this ap-
pears to be true in rqdents, but such an effect of thymus removal has not been detected In dogs or humans." Note that anti-
gen presentation was depicted via the macrophages rather than by the dendritic cells (which were not described until 4 years later.74 
The principal gap in the 1969 hypothesis was the failure to stipulate the location of the immune activation (by permission of 
WB Saunders). 
there had been ·only one study with substantive evi-
dence that clonal exhaustion-deletion actually ex-
isted,86 numerous confirmatory reports have been pub-
lished since.87-92 Moreover, the critical importance of 
acute clonal exhaustion-deletion has been confirmed 
directly in experimental heart and liver transplantation 
models.47.53.93 
The persistence of the disseminated donor leuko-
cytes for as long as 3 decades implied (as was subse-
quently proved94.95) that precursor or stem cells are in-
cluded in the organ's passenger leukocytes. After organ 
transplantation, donor leukocytes briefly constitute 
1 % to 20% of the recipient circulating mononuclear 
cells (Fig. 3, upper graph). Although the number of the 
donor cells is greatest with transplantation of leukocyte-
rich organs (e.g., the liver), the same events on a smaller 
scale occur with transplantation of the kidney and 
heart.46 
Whatever the organ, the donor cells are multi-
lineage, and include many of the dendritic cells 
(DCs)46,48.70.82.96-98 that previously had been associated 
with antigenicity and rejection99.100 rather than toler-
ance. Individual samples from organ recipients often 
do not contain donor leukocytes, which wax and 
wane. IOI •102 However, disseminated donor cells includ-
ing DCs, or other lineages, are consistently demonstra-
ble if host non-lymphoid and lymphoid tissues and 
blood samples are thoroughly studied in rodents bearing 
long-term grafts.46,48.t03 
Thus, it had become obvious that both the engrafted 
organ and the recipient become genetic composites 
(Fig. 4A). It also has been established that the extent of 
donor leukocyte chimerism in the recipient is reflected 
or .exceeded by the quantity of donor leukocytes in t~e 
graft.96.104 In fact, Sakamoto et a1. 105 have shown that 
the organ allograft, whose parenchymal cells are syn-
geneic to the donor passenger leukocytes, provides the 
optimal microenvironment for donor leukocytes includ-
ing the precursor and stem cells that presumably are re-
sponsible for the multilineage nature of micro- as well 
1 
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FIG. 3. The dynamic events after transplantation of all or-
gans, exemplified here by intestinal engraftment. Upper 
Panel: The surge of migratory donor mononuclear leukocytes in 
the recipient blood during the first 2 or 3 weeks posttransplanta-
tion. Lower Panel: The contemporaneous disappearance of the 
passenger leukocytes from the allograft: these were replaced· 
by recipient cells of the same lineages (schematically redrawn 
from data in Iwaki et al [81]). (Reprinted from Starzl et al. Trans· 
plant Proc 1999;31 :1406-1411. with permission.) 
as macrochimerism.48,96 Therefore, the organ allograft 
may be a critical site from which donor leukocytes· are 
renewed and exported to destinations in the host. 105 
A mirror image condition exists after bone marrow 
transplantation in which the dominant cell population is 
donor106 (Fig. 4B). As demonstrated by Przepiorka et 
Immunosuppression 
al. I07 and by Wessman et al.,108 a trace residual popula-
tion of host leukocytes can be found in essentially all 
stable human bone marrow recipients who previously 
had been thought to have complete donor leukocyte 
chimerism. 
PREVIOUS ENIGMAS 
In the context developed with this new information, 
the donor and host leukocytes in organ recipients re-
spond reciprocally (i.e., they mount HVG and GVH 
responses), and also can present antigen and induce 
variable degrees of specific non-reactivity (toler-
ance) 16,46.70,82-84, 106,109 (Fig. 5), If a significant level of 
mutual tolerance does not occur, one of the immune 
competent populations will destroy the other, this may 
be manifested at one extreme by rejection, at the other 
by graft-versus-host disease (GVHD), or by some com-
bination of the 2 kinds of responses46,109 (Fig, 5), The 
time course of the tolerance induction is highly variable. 
However, the progression from the immunologic con-
frontation to either early or delayed graft loss, or to a 
variable stable state of graft acceptance (with or without 
immunosuppression), is monitored clinically by serial 
changes in organ allograft function. 
The dynamic modulation of the two immunocom-
petent leukocyte populations, each by the other, readily 
explains the poor progriostic value of human leukocyte 
antigen (HLA) matching for any kind of organ trans-
plantation 70,82,110 and especially transplantation of the 
leukocyte-rich liver.1Il,112 The nullification effect also 
explains why GVHD rarely occurs after transplantation 
of immunologically active organs such as the intestine 
and liver, providing the recipients have not been condi-
tioned with cytoablation and donot have underlying im-
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mune cells (i.e .. leukocytes) and are therefore genetic composites (i.e., chimeric), 
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FIG. 5. Contemporaneous host-versus-graft (HVG) and graft-versus-host (GVH) reactions after transplantation. Failure is 
defined as the inability to control rejection, GVHO, or sometimes both. Acute reciprocal clonal exhaustion after successful transplan-
tation is maintained subsequently by chimerism-dependent low-grade stimulation of both leukocyte populations. The responses may 
wax and wane. 
mune deficiency disorders. Deletion of the host arm by 
cytoablation, as is routinely done before clinical bone 
marrow transplantation, shifts immune dominance to 
the donor hematolymphopoietic cells, predisposes the 
recipient to GVHD, and is responsible for essentially all 
of the disparities between bone marrow transplantation 
and organ transplantation (Table 2). 
It also was apparent why the liver is more tolero-
genic than other organs. The leukocyte load contained 
in the normal liver is many times greater than that car-
ried by any other organ, and it contains a larger propor-
tion of immature precursor cells and cells of myeloid 
lineage.46 As a corollary, it was predicted that recipients 
of organs less well-endowed with leukocytes could be 
safely infused with adjunct· donor bone marrow cells 
(BMC).113-115 In practice, BMC infusion has been 
shown to be safe in such patients and even in recipients 
of liver and intestinal allografts. However, the need to . 
provide the same immunosuppression as for conven-
tional transplantation of the various organs has imposed 
TABLE 2. Differences between Clinical Organ 
Transplantation and Bone Marrow Transplantation 
Organ Bone Marrow 
Feature Transplal1latioll Trallsplalllatioll 
Host cytoablation No Yes * 
HLA matching Not essential Critical 
Principal complication Rejection Graft -vers us-
host disease 
Immunosuppression-free Uncommon Common 
Term for success Acceptance Tolerance 
*This therapeutic step allows a relatively unopposed graft-versus-host 
reaction and accounts for the other differences. 
a fundamental limitation on the efficacy of the adjunct 
BMC strategy (see discussion below). 
Finally, the ostensible differences between the 
adaptive immune response to allografts and the analo-
gous response to microorganisms were explained by the 
double immune reaction after transplantation versus the 
single host versus pathogen response of infections. Mi-
croorganisms that induce an MHC-restricted adaptive 
immune response are generally intracellular, and have 
no or low cytopathic qualities. 11 6-118 Host cytolytic T 
lymphocytes recognize only microorganism-derived 
peptides that are presented in the context of host MHC 
molecules. Because elimination of all the infected cells 
could disable or !'!ven kill the host, the mechanism of 
clonal exhaustion-deletion has evolved with which the 
immune response can be tempered or terminated, allow-
ing both host and pathogen to survive. 109,116-120 
The highly variable clinical manifestations of 
clonal exhaustion-deletion in a patient infected with dis-
seminated non-cytopathic microorganisms (e.g., the 
common hepatitis viruses) versus the clinical findings 
in the organ recipient are shown in Figure 6A-C. In one 
scenario, the pathogen (antigen) load may rapidly in-
crease during the so-called latent period, but then be 
dramatically and efficiently reduced by antigen-specific 
effector T-cells. Following control of the infection, the 
cytotoxic T lymphocytes (CTL) subside (Fig. 6B). The 
events are similar to those of irreversible organ rejec-
tion (or rarely GVHD) in the unmodified or ineffec-
tively treated recipient (Fig. 6, subtext of panel B). 
Alternatively, however, such infections may lead to 
a continuously high antigen load and an antigen specific 
immunologic collapse (Fig. 6A). The resulting asymp-
tomatic carrier state is analogous to unqualified accep-
... 
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FIG. 6. Potential outcomes after infection with non-cytopathic microorganisms and analogies (expressed as Rejection or 
graft-versus-host disease) to organ and bone marrow transplantation. The horizontal axis denotes time. The vertical axis shows 
the magnitude of the viral load (v, solid line), and the host immune response (IR, dashed line). 
tance of an allograft. This kind of result after transplan-
tation, which may include independence from immuno-
suppression, is not often achieved by organ recipients 
and usually is associated with donor-recipient compati-
bility of HLA alleles (a good tissue match). Complete 
tolerance induced by an organ is a mirror image version 
of succ~ssful bone marrow transplantation (Figs. 4 and 
5; also compare panel A [organ-induced tolerance] with 
panel D [BMC-induced tolerance in a cytoablated 
recipient]). 
Between the 2 extremes of destructive (protective) 
immunity and a carrier (tolerant) state, a persistent in-
fectizms agent may induce an unrelenting immune re-
sponse that results in serious immunopathology such as 
the chronic active hepatitis following a B or C virus in-
f~ctionK This is equivalent to chronic rejection (or un-
commonly GVHD) after liver transplantation (Fig. 6C). 
Chronic rejection may range from aggressive to indo-
lent, despite the best immllnosuppression available 
today. 
IMMUNE REGULATION 
We have proposed that the HVG and GVH re-
sponses of transplantation as well as the responsiveness 
or unresponsiveness to the antigens of pathogens, tu-
mors, and self are governed by the migration and local-
ization of the respective antigens. I 09 The donor passen-
ger leukocytes represent the only mobile donor antigen 
in an organ allograft that is capable of reaching host-
lymphoid organs in large quantity. After organ trans-
plantation, the donor leukocytes migrate hematoge-
nously to the recipient lymphoid organsl21-123 (see Fig. 
3) where they may induce and exhaust antigraft T cells 
while activated donor antihost T cells are deleted. 109 If 
the respective donor and recipient alloantigens do not 
have access to organized lymphoid collections (epito-
mized by but not limited to the lymphoid organs) HVG 
and GVH cytotoxic T cell responses either are not 
induced (immune indifference) or cannot be sus-
tained. J09,116--118,124 Thus, the only 2 mechanisms needed 
to explain all permutations of immune responsiveness 
or non-responsiveness are clonal exhaustion-deletion 
and immune indifference. 
Once initiated, termination of the immune response 
occurs by 2 kinds of apoptosis, each with distinct 
molecular pathways (reviewed by Lenardo I25). If one 
leukocyte population eliminates the other, its antigen-
specific clonal expansion ceases, stopping the secretion 
of IL2 and other pro inflammatory molecules (corre-
sponding to Fig. 6B). The ensuing "passive" apoptosis 
of the cytokine-deficient clone requires new protein 
synthesis, is strongly inhibited by Bcl-2 and related 
anti-apoptotic molecules, and is thought to involve mi-
tochondrial apoptosis mechanisms rather than the death 
cytokines such as Fas ligand (FasL) and tumor necrosis 
factor (TNF).125 
In contrast, organ engraftment occurs when the al-
loantigen is not eliminated and when the continuing re-
sponse is terminated by apoptosis involving FasL and 
TNFI25 If the clonal exhaustion-deletion is complete 
enough, the recipient may become immunosuppression-
independent (Fig. 6A). With the partial tolerance that usu-
ally characterizes immunosuppression-dependent organ 
"acceptance" both kinds of apoptosis may be in-
volved, 126.127 corresponding to some version of Figure 6C. 
The significance of the patchy donor leukocyte (mi-
cro) chimerism remaining after the acute post-transplant 
period has been questioned because of the inconsistency 
I 
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with which donor leukocytes can be found in blood or 
tissue samples from organ recipients; the development 
of acute or chronic rejection despite ch.imerism; and 
the i'nability to use microchimerism to guide post-
transplantation drug weaning. Far from eroding the sig-
nificance of microchimerism, these observations (sum-
marized in 1}8) are readily accommodated by the migra-
tion/loiD~dization cuncept.-l6.70.82.109 tvloreover, most of 
the o'-.lensibly negative studies have consisted essen-
tially of looking for chimerism in single blood samples. 
With serial sampling, Terakura et a!. m have shown 
in a rodent allograft model that a large proportion of the 
donor leukocytes surviving the early post-transplant pe-
riod leave the blood and lymphoid tissues during the 
first 60 transplant days and find niches in non-lymphoid 
tissues and organs of the host such as the skin, and par-
ticularly in the allograft itself.96.104 which may provide 
an optimal syngeneic environment for donor precursor 
and stem cells. lOS Periodic leakage of the chimeric cells 
from such non-lymphoid areas to the host lymphoid 
compartment after transplantation has been suggested 
as an explanation for the maintenance of clonal exhaus-
tion,109.124 analogous to the stable equilibrium between 
destructive and non-destructive immunity described by 
Ohashi et a!. 130. 131 in a model of autoimmune diabetes 
mellitus. 
In experimental animals, in which a complete 
search for donor cells is possible. chimerism always can 
be found in stable organ recipients.l03.132 In contrast, the 
disappearance of micro chimerism in an organ recipient 
p'resages loss of the outlying allograft from chronic or 
acute rejection.46.98.133 Allograft rejection was associ-
ated with thymus-dependent recovery of precursor CTL 
in the mouse model used by Ehl et a1. 133 Thus, persis-
tence of donor leukocyte chimerism is a prerequisite for, 
but not synonymous with and not'a consequence of, the 
evolution of organ-allograft acceptance under clinically 
relevant circumstances. 70.82.109 
A THERAPEUTIC IMPASSE? 
It is self-evident why it has been so difficult in hu-
man organ recipients to achieve the closely related ob-
jectives of drug-free tolerance and freedom from 
chronic rejection, and why these objectives are achieved 
more frequently with the leukocyte-rich liver than with 
other less well endowed organ allografts. Tolerance in-
duction, no matter what the organ, depends on the acute 
clonal activation induced by the migratory donor leuko-
cytes. However, the prevention with immunosuppres-
sion of destructive immunity (i.e., rejection) for long 
enough to allow the variable induction of tolerance has 
been the sine qua non of organ transplantation. In turn, 
the penalty for inhibiting either the critical step of cell 
migration to the host lymphoid organs, or the subse-
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quent immune activation (immunosuppressants do 
both) may be the inability to ever stop drug therapy. In 
such cases, the reduction of maintenance immunosup-
pression below the threshold necessary to complement 
the variably incomplete tolerance, is followed by the 
disappearance of the donor leukocytes from the host tis-
sues and allograft, and the development of chronic re-
jection (Fig. 6C). 
This chain of events is seen in the majority of hu-
man recipients of long surviving organ allografts, but 
with the lowest incidence of chronic rejection in liver 
recipients. Clinical efforts to facilitate tolerance in or-
gan recipients with adjunct donor BMC have been ham-
pered by the fact that the same potentially antitolero-
genic immunosuppression is required as that used for 
conventional organ transplantation. 113 The low level 
chimerism normally found in organ recipients has been 
increased many fold by the additional load of donor 
leukocytes and has been reported in some studies to 
result in a higher incidence of donor specific non-
reactivity.113-IIS.134 However, discontinuance of im-
munosuppression has not been achieved. 
DERIVATIVE FALSE DOGMAS 
The paradigm that emerged from the chimerism 
discoveries has necessitated reevaluation of other as-
pects of transplantation immunology. Studies of allo-
geneic tolerance mechanisms commonly has been done 
with "parking" techniques,7S.76,79.I3S-137 At Stage 1, tis-
sue or an organ is engrafted with the aid of recipient ir-
radiation, a few post-transplant doses of an immunosup-
pressant or in spontaneous tolerance liver transplant 
modelsl36.137 without treatment. At Stage 2 of a proto-
type experiment, the retransplanted allograft is not re-
jected by naIve animals of the original recipient strain. 
It is self evident that parking experiments are inap-
propriate for most studies of tolerance mechanisms. 
Stage 1, if it is successful, is an example of tolerance in-
duction per se, although the term tolerance has been stu-
diously avoided by most investigators using these mod-
els. By replacing most of the passenger leukocytes with 
those of the strain to which the altered graft is secondar-
ily transplanted, the essential tolerogenic step of im-
mune activation is eliminated from the retransplantation 
stage. In addition, the donor strain leukocytes in the 
parked allografts are not uniformly l'eplaced lO4 as has 
been commonly assumed. Furthermore, neither the 
residual donor cells nor the replacement cells from the 
recipient can be viewed as either naIve or purely in 
terms of antigen. Finally, completeness of graft "accep-
tance" during the parking or after retransplantation can-
not be assumed without examining the allograft for 
histopathological signs of chronic rejection and without 
analyzing its leukocyte composition. 
I 
I 
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The most important dogma to be questioned is the 
hitherto unchallenged assumption that passenger leuko-
cytes are highly immunogenic while parenchymal cells 
(especially hepatocytes) are not. The immunogenicity 
of non parenchymal cells has been widely attributed to 
the expression by these bone marrow derived leuko-
cytes of MHC class II and/or co-stimulatory (i.e., B7) 
molecules. In the antigen migration/localization para-
digm, 109 passenger leukocytes appear to be uniquely im-
munogenic primarily because of their ability to migrate 
to lymphoid organs whereas organ parenchymal cells 
are non-immunogenic largely, if not entirely, because 
they are immobilized within the organ architecture. This 
would readily explain the otherwise enigmatic finding 
by Bumgardner and Orosz et aI.,138-140 that when hepa-
tocytes are isolated and given by infusion, they are as 
immunogenic, if not more so, than hepatic passenger 
leukocytes. 
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